Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
In insulin-naïve people with T2D who had suboptimal HbA1c with tirzepatide, significant reductions in HbA1c and improvements in the percentage of people reaching HbA1c target of < 7.0% were observed with Gla-300. Infographic and video abstract available for this article. Please follow the digital features link under the abstract. A video abstract of the Deliver-T study, which evaluated glycaemic control in people with T2D previously treated with tirzepatide and newly intensified with insulin glargine 300 U/mL (Gla-300).
Authors
- Dı́dac Mauricio (ORCID: https://orcid.org/0000-0002-2868-0250)
- Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
- Robert Ritzel (ORCID: https://orcid.org/0000-0001-5417-4135)
- Timothy S. Bailey (ORCID: https://orcid.org/0000-0003-4178-3462)
- Lichen Hao
- Melanie Jane Davies (ORCID: https://orcid.org/0000-0002-9987-9371)
- Lintu MK
- Aileen Mabunay
Institutions
- University of Leicester (GB)
- Peking University (CN)
- Hospital de Sant Pau (ES)
- München Klinik Bogenhausen (DE)
- München Klinik Schwabing (DE)
- AMCR Institute (US)
- Sanofi (United States) (US)
- Sanofi (India) (IN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s13300-025-01798-5
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi